Medical technology

Global Bioabsorbable Stents Market Forecast 2020-2025 Featuring Key Players - Abbot Laboratories, Elixir Medical, Reva Medical, Kyoto Medical Planning - ResearchAndMarkets.com

Tuesday, October 20, 2020 - 9:28am

To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.

Key Points: 
  • To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.
  • The bioabsorbable stents market is classified on the basis of material used for manufacturing the products including polymeric and metallic.
  • Metal bioabsorbable stents are luring the medical device providers as they have the potential to perform similarly to stainless steel metal stents.
  • The key players in bioabsorbable stents market include:

SI-BONE To Report Third Quarter 2020 Financial Results on November 2, 2020

Monday, October 19, 2020 - 9:05pm

SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market close on Monday, November 2, 2020.

Key Points: 
  • SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market close on Monday, November 2, 2020.
  • Live audio of the webcast will be available on the Investors section of the companys website at: www.si-bone.com .
  • SI-BONEis a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.
  • SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. 2020 SI-BONE, Inc. All Rights Reserved.

MED-EL: First Surgeries Ever in Europe with a Totally Implantable Cochlear Implant

Monday, October 19, 2020 - 7:00am

On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI).

Key Points: 
  • On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI).
  • A young man with close to profound hearing loss was the first person in Europe to receive a fully implantable cochlear implant.
  • Totally implantable cochlear implants will be the most innovative and sophisticated technology in the field of hearing solutions.
  • Several more surgeries with the totally implantable cochlear implant will follow in Lige and Munich in the next couple of months as part of the clinical feasibility study.

MED-EL: First Surgeries Ever in Europe with a Totally Implantable Cochlear Implant

Monday, October 19, 2020 - 7:00am

On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI).

Key Points: 
  • On 24 September, the first person in Europe received a novel totally implantable cochlear implant (TICI).
  • A young man with close to profound hearing loss was the first person in Europe to receive a fully implantable cochlear implant.
  • Totally implantable cochlear implants will be the most innovative and sophisticated technology in the field of hearing solutions.
  • Several more surgeries with the totally implantable cochlear implant will follow in Lige and Munich in the next couple of months as part of the clinical feasibility study.

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

Saturday, October 17, 2020 - 5:00pm

The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.

Key Points: 
  • The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.
  • The high TLF reported in both OPTIMIZE treatment groups is driven by the 25% of study subjects assessed peri-procedurally with high-sensitivity-troponin.
  • We are deeply grateful to each and every one of the patients, investigative team members and support personnel contributing to the OPTIMIZE study.
  • Headquartered in New Providence, New Jersey, Svelte Medical Systems ( www.sveltemedical.com ) is a privately-held company engaged in the development of highly deliverable balloon expandable stents.

Global Peripheral Stents Market Insights to 2024 - Players Include Abbott, Biotronik and Boston Medical Among Others - ResearchAndMarkets.com

Friday, October 16, 2020 - 3:26pm

The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.
  • This report was developed using extensive primary and secondary research by the publisher's analysts.
  • Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market share for the top suppliers by product segment.
  • Devices in this global market analysis include peripheral vascular stents, iliac artery stents, biliary stents, tracheobronchial stents.

Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

Friday, October 16, 2020 - 1:05pm

Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.

Key Points: 
  • Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.
  • This study suggests that in right heart failure, reducing the time between shock onset and initiation of Impella RP is a key element of proper patient support.
  • A second study presented at TCT aims to help clinicians identify early triggers of right heart failure.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

Friday, October 16, 2020 - 12:05pm

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.

Key Points: 
  • Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.
  • Researchers found an 18% relative improvement in overall survival in the recent cohort, indicating an associated benefit to placing Impella pre-PCI.
  • It found that placing Impella pre-PCI in AMICS patients is associated with higher survival than placing Impella post-PCI, especially in women.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD)

Friday, October 16, 2020 - 7:55am

Pixium Vision's management team will give an update on their Prima Bionic Vision System.

Key Points: 
  • Pixium Vision's management team will give an update on their Prima Bionic Vision System.
  • Dr. Sahel was a co-founder of Fovea Pharmaceuticals, StreetLab, GenSight Biologics, Pixium Vision, Sparing Vision.
  • Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturized wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age- Related Macular Degeneration (AMD).
  • Pixium Vision has been qualified as an Innovative Company by Bpifrance
    This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business.

Global Defibrillator (Implantable, External) Markets, 2015-2019 & 2020-2025

Thursday, October 15, 2020 - 8:30pm

The Global Defibrillator Market is projected to display significant growth represented by a CAGR of 3.59% during 2020 - 2025.

Key Points: 
  • The Global Defibrillator Market is projected to display significant growth represented by a CAGR of 3.59% during 2020 - 2025.
  • The Global Defibrillator Market was valued at USD 10.71 Billion in the year 2019 with North America leading the regional market share.
  • The Defibrillator market is expected to grow on the back of growing geriatric population and an increased prevalence of cardiovascular disease among young population.
  • Under the product type, Implantable Defibrillator is witnessing rising demand with growing awareness among people about role of defibrillator in reducing the mortality rate during sudden cardiac arrest.